Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients

Journal of Hepatology

Volumn 68, Issue 4, 2018, Pages 764-772

  Lee, Yong ho ^a   Kim, Kwang Joon ^a   Yoo, Myung eun ^a   Kim, Gyuri ^a   Yoon, Hye jin ^a   Jo, Kwanhyeong ^a   Youn, Jong Chan ^b,c   Yun, Mijin ^a   Park, Jun Yong ^a   Shim, Chi Young ^a,c   Lee, Byung Wan ^a   Kang, Seok Min ^a,c   Ha, Jong Won ^a,c   Cha, Bong Soo ^a   Kang, Eun Seok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c Yonsei University Health System   (South Korea)

Author keywords

Diastolic heart dysfunction; Insulin resistance; Liver fibrosis; Non alcoholic fatty liver disease; Obesity; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; FATTY LIVER INDEX; FEMALE; GLUCOSE TRANSPORT; HEART LEFT ATRIUM; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; LIVER FIBROSIS; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; NAFLD FIBROSIS SCORE; NONALCOHOLIC FATTY LIVER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; TISSUE DOPPLER IMAGING; TRANSIENT ELASTOGRAPHY; YOUNG ADULT; AGED; CARDIAC MUSCLE; COMPLICATION; DIAGNOSTIC IMAGING; DIASTOLE; ECHOCARDIOGRAPHY; ELASTOGRAPHY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; DIASTOLE; ECHOCARDIOGRAPHY; ELASTICITY IMAGING TECHNIQUES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85040445290     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.11.023     Document Type: Article

References (68)

1. Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
2. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
3. Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
4. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
5. Lee, Y.H., Kim, S.U., Song, K., Park, J.Y., Kim do, Y., Ahn, S.H., et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). Hepatology 63 (2016), 776–786.
6. Satapathy, S.K., Sanyal, A.J., Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 35 (2015), 221–235.
7. Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
8. Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7 (2009), 234–238.
9. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
10. Schindhelm, R.K., Dekker, J.M., Nijpels, G., Bouter, L.M., Stehouwer, C.D., Heine, R.J., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007), 391–396.
11. Azzam, H., Malnick, S., Non-alcoholic fatty liver disease - the heart of the matter. World J Hepatol 7 (2015), 1369–1376.
12. Lautamaki, R., Borra, R., Iozzo, P., Komu, M., Lehtimaki, T., Salmi, M., et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 291 (2006), E282–E290.
13. Goland, S., Shimoni, S., Zornitzki, T., Knobler, H., Azoulai, O., Lutaty, G., et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40 (2006), 949–955.
14. Fotbolcu, H., Yakar, T., Duman, D., Karaahmet, T., Tigen, K., Cevik, C., et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 17 (2010), 457–463.
15. Masoud, W.G., Ussher, J.R., Wang, W., Jaswal, J.S., Wagg, C.S., Dyck, J.R., et al. Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc Res 101 (2014), 30–38.
16. Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
17. Zile, M.R., Brutsaert, D.L., New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105 (2002), 1387–1393.
18. Bhatia, R.S., Tu, J.V., Lee, D.S., Austin, P.C., Fang, J., Haouzi, A., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269.
19. Kim, G., Jo, K., Kim, K.J., Lee, Y.H., Han, E., Yoon, H.J., et al. Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes. Cardiovasc Diabetol, 14, 2015, 148.
20. He, Z.X., Hedrick, T.D., Pratt, C.M., Verani, M.S., Aquino, V., Roberts, R., et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia. Circulation 101 (2000), 244–251.
21. Oh, S.W., Obesity and metabolic syndrome in Korea. Diabetes Metab J 35 (2011), 561–566.
22. Standards of medical care in diabetes–2014. Diabetes Care 37 (2014), S14–S80.
23. Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005), 1440–1463.
24. Shim, C.Y., Park, S., Choi, D., Yang, W., Cho, I., Choi, E., et al. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. J Am Coll Cardiol 57 (2011), 1226–1233.
25. Devereux, R.B., Alonso, D.R., Lutas, E.M., Gottlieb, G.J., Campo, E., Sachs, I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986), 450–458.
26. Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005), 1115–1140.
27. Nagueh, S.F., Smiseth, O.A., Appleton, C.P., Byrd Iii, B.F., Dokainish, H., Edvardsen, T., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 29 (2016), 277–314.
28. Lee, Y.H., Bang, H., Park, Y.M., Bae, J.C., Lee, B.W., Kang, E.S., et al. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One, 9, 2014, e107584.
29. Chon, Y.E., Kim, K.J., Jung, K.S., Kim, S.U., Park, J.Y., Kim do, Y., et al. The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. Yonsei Med J 57 (2016), 885–892.
30. Saadeh, S., Younossi, Z.M., Remer, E.M., Gramlich, T., Ong, J.P., Hurley, M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002), 745–750.
31. Kim, S.U., Ahn, S.H., Park, J.Y., Kang, W., Kim, D.Y., Park, Y.N., et al. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol 43 (2009), 267–271.
32. Chon, Y.E., Jung, K.S., Kim, S.U., Park, J.Y., Park, Y.N., Kim do, Y., et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 34 (2014), 102–109.
33. Williams, G., Kolodny, G.M., Retrospective study of coronary uptake of 18F-fluorodeoxyglucose in association with calcification and coronary artery disease: a preliminary study. Nucl Med Commun 30 (2009), 287–291.
34. Abele, J.T., Fung, C.I., Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology 254 (2010), 917–924.
35. Paquet, N., Albert, A., Foidart, J., Hustinx, R., Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 45 (2004), 784–788.
36. Boellaard, R., Krak, N.C., Hoekstra, O.S., Lammertsma, A.A., Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 45 (2004), 1519–1527.
37. Perseghin, G., Lattuada, G., De Cobelli, F., Esposito, A., Belloni, E., Ntali, G., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47 (2008), 51–58.
38. Hallsworth, K., Hollingsworth, K.G., Thoma, C., Jakovljevic, D., MacGowan, G.A., Anstee, Q.M., et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 58 (2013), 757–762.
39. VanWagner, L.B., Wilcox, J.E., Colangelo, L.A., Lloyd-Jones, D.M., Carr, J.J., Lima, J.A., et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 62 (2015), 773–783.
40. Fallo, F., Dalla Pozza, A., Sonino, N., Lupia, M., Tona, F., Federspil, G., et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 19 (2009), 646–653.
41. Bonapace, S., Perseghin, G., Molon, G., Canali, G., Bertolini, L., Zoppini, G., et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35 (2012), 389–395.
42. Kim, N.H., Park, J., Kim, S.H., Kim, Y.H., Kim, D.H., Cho, G.Y., et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100 (2014), 938–943.
43. Moller, S., Bernardi, M., Interactions of the heart and the liver. Eur Heart J 34 (2013), 2804–2811.
44. Wang, Y., Tuomilehto, J., Jousilahti, P., Salomaa, V., Li, B., Antikainen, R., et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart 99 (2013), 163–167.
45. Wannamethee, S.G., Whincup, P.H., Shaper, A.G., Lennon, L., Sattar, N., Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol 32 (2012), 830–835.
46. Petta, S., Argano, C., Colomba, D., Camma, C., Di Marco, V., Cabibi, D., et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 62 (2015), 928–933.
47. Iacobellis, G., Corradi, D., Sharma, A.M., Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2 (2005), 536–543.
48. Rolo, A.P., Teodoro, J.S., Palmeira, C.M., Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52 (2012), 59–69.
49. Targher, G., Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol 45 (2006), 879–881 [Author reply 881-882].
50. Bhatia, L.S., Curzen, N.P., Calder, P.C., Byrne, C.D., Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 33 (2012), 1190–1200.
51. Granzow, M., Schierwagen, R., Klein, S., Kowallick, B., Huss, S., Linhart, M., et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 60 (2014), 334–348.
52. Munzel, T., Gori, T., Keaney, J.F. Jr., Maack, C., Daiber, A., Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J 36 (2015), 2555–2564.
53. Day, S.M., The ubiquitin proteasome system in human cardiomyopathies and heart failure. Am J Physiol Heart Circ Physiol 304 (2013), H1283–H1293.
54. Lee, Y.H., Jung, K.S., Kim, S.U., Yoon, H.J., Yun, Y.J., Lee, B.W., et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). J Hepatol 63 (2015), 486–493.
55. Yoo, H.J., Choi, K.M., Hepatokines as a link between obesity and cardiovascular diseases. Diabetes Metab J 39 (2015), 10–15.
56. Heinrichsdorff, J., Olefsky, J.M., Fetuin-A: the missing link in lipid-induced inflammation. Nat Med 18 (2012), 1182–1183.
57. Chang, W.T., Tsai, W.C., Wu, C.H., Lee, Y.W., Tai, Y.L., Li, Y.H., et al. Fetuin-A as a predicator of sarcopenic left ventricular dysfunction. Sci Rep, 5, 2015, 12078.
58. Halley, C.M., Houghtaling, P.L., Khalil, M.K., Thomas, J.D., Jaber, W.A., Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med 171 (2011), 1082–1087.
59. van Riet, E.E., Hoes, A.W., Wagenaar, K.P., Limburg, A., Landman, M.A., Rutten, F.H., Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18 (2016), 242–252.
60. Tsang, T.S., Barnes, M.E., Gersh, B.J., Bailey, K.R., Seward, J.B., Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 90 (2002), 1284–1289.
61. Beinart, R., Boyko, V., Schwammenthal, E., Kuperstein, R., Sagie, A., Hod, H., et al. Long-term prognostic significance of left atrial volume in acute myocardial infarction. J Am Coll Cardiol 44 (2004), 327–334.
62. Meris, A., Amigoni, M., Uno, H., Thune, J.J., Verma, A., Kober, L., et al. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. Eur Heart J 30 (2009), 56–65.
63. Poulsen, M.K., Dahl, J.S., Henriksen, J.E., Hey, T.M., Hoilund-Carlsen, P.F., Beck-Nielsen, H., et al. Left atrial volume index: relation to long-term clinical outcome in type 2 diabetes. J Am Coll Cardiol 62 (2013), 2416–2421.
64. Colloredo, G., Guido, M., Sonzogni, A., Leandro, G., Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39 (2003), 239–244.
65. Regev, A., Berho, M., Jeffers, L.J., Milikowski, C., Molina, E.G., Pyrsopoulos, N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002), 2614–2618.
66. Gaia, S., Carenzi, S., Barilli, A.L., Bugianesi, E., Smedile, A., Brunello, F., et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 54 (2011), 64–71.
67. de Lédinghen, V., Vergniol, J., Capdepont, M., Chermak, F., Hiriart, J., Cassinotto, C., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 60 (2014), 1026–1031.
68. Shen, F., Zheng, R., Mi, Y., Wang, X., Pan, Q., Chen, G., et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 20 (2014), 4702–4711.